

PATENT APPLICATION

10/552575

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DAVIDSON *et al.*

Serial No: TBA

Filed: Herewith

)
)
)
)
)
)

Group Art No. TBA

Examiner: TBA

Docket No. 010180.00042

For: AZETIDINECARBOXAMIDE
 DERIVATIVES AND THEIR USE IN THE
 TREATMENT OF CB1 RECEPTOR MEDIATED
 DISORDERS

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
 220 20th Street S.
 Customer Window
 Crystal Plaza Two, Lobby, Room 1B03
 Arlington, VA 22202


Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicants submit herewith Form PTO-1449 identifying information for consideration by the Examiner. A copy of the cited document is also enclosed along with the International Search Report.

If the Patent and Trademark Office determines that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.Date: 10/12/05

By: 
 Susan A. Wolffe
 Registration No. 33,568

Banner & Witcoff, Ltd.
 Customer No. 22907

SAW/sdm

USPTO Form 1449, U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 1 of 1		Attorney Docket No. 010180.00042	Serial No. TBA
		10/552575	
		Applicant(s): DAVIDSON et al Filing Date: October 12, 2005	
		Group: TBA	

U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
	WO 99/37612 A	29 July 1999	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.